Literature DB >> 21228179

Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.

Erik D Roberson1, Brian Halabisky, Jong W Yoo, Jinghua Yao, Jeannie Chin, Fengrong Yan, Tiffany Wu, Patricia Hamto, Nino Devidze, Gui-Qiu Yu, Jorge J Palop, Jeffrey L Noebels, Lennart Mucke.   

Abstract

Alzheimer's disease (AD), the most common neurodegenerative disorder, is a growing public health problem and still lacks effective treatments. Recent evidence suggests that microtubule-associated protein tau may mediate amyloid-β peptide (Aβ) toxicity by modulating the tyrosine kinase Fyn. We showed previously that tau reduction prevents, and Fyn overexpression exacerbates, cognitive deficits in human amyloid precursor protein (hAPP) transgenic mice overexpressing Aβ. However, the mechanisms by which Aβ, tau, and Fyn cooperate in AD-related pathogenesis remain to be fully elucidated. Here we examined the synaptic and network effects of this pathogenic triad. Tau reduction prevented cognitive decline induced by synergistic effects of Aβ and Fyn. Tau reduction also prevented synaptic transmission and plasticity deficits in hAPP mice. Using electroencephalography to examine network effects, we found that tau reduction prevented spontaneous epileptiform activity in multiple lines of hAPP mice. Tau reduction also reduced the severity of spontaneous and chemically induced seizures in mice overexpressing both Aβ and Fyn. To better understand these protective effects, we recorded whole-cell currents in acute hippocampal slices from hAPP mice with and without tau. hAPP mice with tau had increased spontaneous and evoked excitatory currents, reduced inhibitory currents, and NMDA receptor dysfunction. Tau reduction increased inhibitory currents and normalized excitation/inhibition balance and NMDA receptor-mediated currents in hAPP mice. Our results indicate that Aβ, tau, and Fyn jointly impair synaptic and network function and suggest that disrupting the copathogenic relationship between these factors could be of therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228179      PMCID: PMC3325794          DOI: 10.1523/JNEUROSCI.4152-10.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  73 in total

1.  Frontotemporal dementia progresses to death faster than Alzheimer disease.

Authors:  E D Roberson; J H Hesse; K D Rose; H Slama; J K Johnson; K Yaffe; M S Forman; C A Miller; J Q Trojanowski; J H Kramer; B L Miller
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

2.  Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.

Authors:  Wesley Farris; Sonja G Schütz; John R Cirrito; Ganesh M Shankar; Xiaoyan Sun; Ana George; Malcolm A Leissring; Dominic M Walsh; Wei Qiao Qiu; David M Holtzman; Dennis J Selkoe
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

3.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

4.  Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy.

Authors:  Rimante Minkeviciene; Sylvain Rheims; Marton B Dobszay; Misha Zilberter; Jarmo Hartikainen; Lívia Fülöp; Botond Penke; Yuri Zilberter; Tibor Harkany; Asla Pitkänen; Heikki Tanila
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

5.  Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression.

Authors:  Joseph Krezowski; Danielle Knudson; Christine Ebeling; Rose Pitstick; Ranjit K Giri; Dale Schenk; David Westaway; Linda Younkin; Steven G Younkin; Karen Hsiao Ashe; George A Carlson
Journal:  Hum Mol Genet       Date:  2004-07-14       Impact factor: 6.150

6.  Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice.

Authors:  Jeannie Chin; Jorge J Palop; Gui-Qiu Yu; Nobuhiko Kojima; Eliezer Masliah; Lennart Mucke
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

7.  Mechanisms of neocortical epileptogenesis in vitro.

Authors:  M J Gutnick; B W Connors; D A Prince
Journal:  J Neurophysiol       Date:  1982-12       Impact factor: 2.714

8.  Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant.

Authors:  T L Williamson; L I Bruijn; Q Zhu; K L Anderson; S D Anderson; J P Julien; D W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

Review 10.  The GSK3 hypothesis of Alzheimer's disease.

Authors:  Claudie Hooper; Richard Killick; Simon Lovestone
Journal:  J Neurochem       Date:  2007-12-18       Impact factor: 5.372

View more
  313 in total

1.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

Review 2.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

Review 3.  Synapses and Alzheimer's disease.

Authors:  Morgan Sheng; Bernardo L Sabatini; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

4.  One Mutation Deserves Another in the Quest for Antiepileptogenesis.

Authors:  Bret N Smith
Journal:  Epilepsy Curr       Date:  2015 Jul-Aug       Impact factor: 7.500

5.  Mechanisms of tau and Aβ-induced excitotoxicity.

Authors:  Susanne P Pallo; John DiMaio; Alexis Cook; Bradley Nilsson; Gail V W Johnson
Journal:  Brain Res       Date:  2015-12-28       Impact factor: 3.252

6.  Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.

Authors:  Chuanzhou Li; Jürgen Götz
Journal:  EMBO J       Date:  2017-09-01       Impact factor: 11.598

Review 7.  Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms.

Authors:  Jeannie Chin; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-13       Impact factor: 2.937

Review 8.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

9.  Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.

Authors:  Keith A Vossel; Kamalini G Ranasinghe; Alexander J Beagle; Danielle Mizuiri; Susanne M Honma; Anne F Dowling; Sonja M Darwish; Victoria Van Berlo; Deborah E Barnes; Mary Mantle; Anna M Karydas; Giovanni Coppola; Erik D Roberson; Bruce L Miller; Paul A Garcia; Heidi E Kirsch; Lennart Mucke; Srikantan S Nagarajan
Journal:  Ann Neurol       Date:  2016-11-07       Impact factor: 10.422

Review 10.  Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.

Authors:  Thomas Arendt; Jens Stieler; Max Holzer
Journal:  J Neural Transm (Vienna)       Date:  2014-12-06       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.